Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T13:26:00.551Z.
Calculation as of: 2026-10-06T13:26:00.551Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 273f4a35489c6dcba82bfbf6813c8f243fa8fa5e32baf23fc33ea9a1b57f5f97
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Compass Therapeutics, Inc.
Market Cap
$172.99M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.04M
Operating Cash Flow Yield
N/A
TTM Avg
0.52%
3Y Avg
0.52%
5Y Avg
7.75%
Market Cap
$174.17M
Operating Cash Flow Yield
N/A
TTM Avg
0.62%
3Y Avg
0.62%
5Y Avg
0.62%
Market Cap
$176.96M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$179.70M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.82M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.12M
Operating Cash Flow Yield
N/A
TTM Avg
11.12%
3Y Avg
9.89%
5Y Avg
9.89%
Market Cap
$160.82M
Operating Cash Flow Yield
N/A
TTM Avg
2.00%
3Y Avg
1.62%
5Y Avg
3.25%
Market Cap
$153.84M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $172.99M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | N/A | 0.52% | 0.52% | 7.75% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | N/A | 0.62% | 0.62% | 0.62% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $184.12M | N/A | 11.12% | 9.89% | 9.89% |
| Inogen, Inc. (INGN)vs › | $160.82M | N/A | 2.00% | 1.62% | 3.25% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
